MBI (1783) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 和康生

MBI (1783) reported revenue of NT$74.4 million for Oct 2026, +17.3% year on year and -15.6% from the previous month. Revenue for Jan–Oct 2026 was NT$706.6 million (+8.7% year on year).

In Oct 2026, it ranked No. 89 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$62 million24/10Nov 2024 NT$73.9 millionDec 2024 NT$69.8 millionJan 2025 NT$67.6 millionFeb 2025 NT$39.7 million25/02Mar 2025 NT$69.9 millionApr 2025 NT$52.9 millionMay 2025 NT$77 millionJun 2025 NT$78.9 million25/06Jul 2025 NT$65.5 millionAug 2025 NT$70.3 millionSep 2025 NT$65.1 millionOct 2025 NT$63.4 million25/10Nov 2025 NT$68.4 millionDec 2025 NT$92.9 millionJan 2026 NT$73 millionFeb 2026 NT$48 million26/02Mar 2026 NT$69.9 millionApr 2026 NT$61.3 millionMay 2026 NT$73.6 millionJun 2026 NT$86.1 million26/06Jul 2026 NT$63.8 millionAug 2026 NT$68.5 millionSep 2026 NT$88.1 millionOct 2026 NT$74.4 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$74.4 million+17.3%-15.6%
Sep 2026NT$88.1 million+35.3%+28.5%
Aug 2026NT$68.5 million-2.5%+7.5%
Jul 2026NT$63.8 million-2.6%-26.0%
Jun 2026NT$86.1 million+9.2%+17.0%
May 2026NT$73.6 million-4.4%+20.1%
Apr 2026NT$61.3 million+15.8%-12.4%
Mar 2026NT$69.9 million+0.1%+45.8%
Feb 2026NT$48 million+20.9%-34.3%
Jan 2026NT$73 million+7.9%-21.4%
Dec 2025NT$92.9 million+33.1%+35.8%
Nov 2025NT$68.4 million-7.4%+7.8%
Oct 2025NT$63.4 million+2.3%-2.6%
Sep 2025NT$65.1 million+3.3%-7.3%
Aug 2025NT$70.3 million+27.9%+7.3%
Jul 2025NT$65.5 million+17.0%-17.0%
Jun 2025NT$78.9 million+38.5%+2.4%
May 2025NT$77 million+18.5%+45.6%
Apr 2025NT$52.9 million+1.6%-24.3%
Mar 2025NT$69.9 million+81.6%+76.2%
Feb 2025NT$39.7 million+6.1%-41.3%
Jan 2025NT$67.6 million+32.1%-3.1%
Dec 2024NT$69.8 million+47.4%-5.5%
Nov 2024NT$73.9 million+32.8%+19.2%
Oct 2024NT$62 million+35.4%-1.7%

Jan–Oct 2026 cumulative: NT$706.6 million (+8.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: MBI vs PEC / MBI vs Lotus Pharm / MBI vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16